Ultragenyx raises $15 million

Ultragenyx Prsident and CEO Emil Kakkis.

Orphan drug developer Ultragenyx Pharmaceutical Inc. has gathered $15.1 million toward a goal of raising $30.1 million, according to a Securities and Exchange Commission filing Monday. The Novato company, started by former BioMarin Pharmaceutical Inc. Chief Medical Officer Emil Kakkis, has won orphan drug designation for two drugs from the Food and Drug Administration as well as from European drug regulators.